Company Performance Metrics
Cyto Wave Technologies (“The Company”) has licensed a first-in-class breakthrough technology platform from the University of Arkansas for Medical Sciences (UAMS) that allows the early non-invasive detection, capturing and targeted destruction of metastatic circulating tumor cells (CTCs) in vivo
The Company is developing a highly-sensitive,
portable device (“iV3″) for real-time detection of CTCs directly in the bloodstream of cancer patients. CTCs are detected by a proprietary laser technology and can then be extracted from the bloodstream. The laser can also potentially destroy CTCs directly.
iV3 has been funded with US$4.4 million from the National Health Institutes/National Cancer Institute, the Department of Defense (DoD) and private investors which has alleviated much of the early risk associated with developing a new breakthrough technology. A human clinical trial in melanoma patients is currently being initiated.
